This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD7 scFv to sFasL. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD7 as well as the biological activity of sFasL. The soluble protein was inactive and required binding to tumor cells expressing CD7 to induce a tumoricidal activity for the treatment of T-cell leukemia. The immunocytokine was applied to eliminate pathogenic synovial fluid Th1 and Treg cells from rheumatoid arthritis and juvenile idiopathic arthritis, thus expanding a possible therapeutic application to chronic inflammatory diseases. This immunocytokine was designed for treating chronic inflammatory diseases.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-183-F(E) | Recombinant Anti-human CD7 Antibody Fab Fragment | IP, Neut, FuncS | Fab |
MHH-183-F(E) | Recombinant Human Anti-human CD7 Antibody Fab Fragment | Neut, WB, FuncS | Fab |
FAMAB-0049CQ-F(E) | Human Anti-CD7 Recombinant Antibody (clone CHT2); Fab Fragment | IHC, FC, Block, IF | Chimeric (mouse/human) Fab |
FAMAB-0050CQ-F(E) | Mouse Anti-CD7 Recombinant Antibody (clone RFT2); Fab Fragment | IHC, FC, Block, IF | Mouse Fab |
There are currently no Customer reviews or questions for ACFP-SH121. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.